Sophie E. Aapkes

Sophie E. Aapkes

Auto-generated profile, based on publicly available information

Sophie E. Aapkes

Department Nephrology, University Medical Center, Groningen, The Netherlands

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2021 in Liver International
Verified
Journal Article
Open access
PDF file
SASophie E. Aapkes
Sophie E. Aapkes
LBLucas H. P. Bernts
Lucas H. P. Bernts
TBThijs R. M. Barten
Thijs R. M. Barten
MBMarjan van Den Berg
Marjan van Den Berg
RGRon T. Gansevoort
Ron T. Gansevoort
JDJoost Drenth
Joost Drenth
Patients suffering from polycystic liver disease can develop large liver volumes, leading to physical and psychological complaints, reducing quality of life. There is an unmet need for new therapies in these patients. Estrogen seems to be a promising target for new therapies. Female sex is the most important risk factor for the presence and severity of disease, estrogen supplementation enhances liver growth and after menopause, liver growth decreases. Experimental studies show the presence of the estrogen receptors alfa and beta on cystic cholangiocytes, and increased in vitro growth after administration of estrogen. In this review, we summarize the available experimental and epidemiological evidence to unravel the role of estrogens and other female hormones in polycystic liver disease. Based on the available evidence, female polycystic liver disease patients should be discouraged from taking estrogen-containing contraceptives or hormone replacement therapy. Since liver growth rates decline after menopause, treatment decisions should be based on measured liver growth in postmenopausal women. Finally, blockage of estrogen receptors or estrogen production is a promising target for new therapies.

29 March 2021 in Drugs in R&D
Verified
Journal Article
Open access
PDF file
SASophie E. Aapkes
Sophie E. Aapkes
RHRobbert J. de Haas
Robbert J. de Haas
LBLucas H. P. Bernts
Lucas H. P. Bernts
CBCharles J. Blijdorp
Charles J. Blijdorp
SDSosha E. I. Dekker
Sosha E. I. Dekker
RZR. Zietse
R. Zietse
Introduction Gallstones are a known adverse effect of somatostatin analogs, but the exact incidence and clinical implications are unknown. Objectives The aim of this study was to investigate the incidence of gallstones on imaging and related complications in unbiased trial data. Methods Data from the DIPAK 1 trial, in which 305 polycystic kidney disease patients were randomized to standard of care (SoC) or lanreotide for 120 weeks, were used. Magnetic resonance imaging (MRI) was performed at baseline and end of treatment and was assessed for the presence, number, and size of gallstones. For all patients who had gallstones at the end of the trial, we obtained follow-up after the trial. Results Of 249 patients with data available, 11 patients randomized to lanreotide and four randomized to SoC had gallstones at baseline. During the study, new gallstones were formed in 19/124 patients using lanreotide (15%) and 1/125 patients receiving SoC (1%). The odds ratio for gallstone formation with lanreotide use was 25.9 (95% confidence interval 3.37–198.8; p < 0.001). Gallstones during lanreotide treatment were multiple (> 20 stones in 69% of patients) and small (≤ 3 mm in 63% of patients). Of the 19 patients with incident gallstones during lanreotide treatment, 9 experienced gallstone-associated complications, 8 of whom experienced gallstone-associated complications after discontinuation of treatment (median time after discontinuation 2.5 years). In patients with gallstones at baseline and in patients receiving SoC, no complications occurred. Conclusions Treatment with a somatostatin analog leads to the formation of multiple, small gallstones that are associated with severe complications, especially after discontinuation of therapy. Clinical Trial Registry Website and Trial Number ClinicalTrials.gov (https://clinicaltrials.gov); NCT01616927.

13 August 2021 in Medicine
Verified
Journal Article
Open access
SASophie E. Aapkes
Sophie E. Aapkes
LBLucas H.P. Bernts
Lucas H.P. Bernts
MBM. van Den Berg
M. van Den Berg
RGRon T. Gansevoort
Ron T. Gansevoort
JDJoost Drenth
Joost Drenth
Rationale: Polycystic liver disease is a rare disease characterized by the growth of numerous cysts in the liver. The liver function remains well preserved, but liver volumes can grow very large, and some patients ultimately need a liver transplantation. Other treatment options are limited and there is an unmet need for new therapeutic options. Patient concerns: We describe a 59-year-old patient with pain in the abdomen, especially when bending forward. Five years ago, she was diagnosed with breast cancer and as an incidental finding a couple of large liver cysts were diagnosed, explaining her abdominal pain. Diagnosis: Polycystic liver disease with several large liver cysts. Interventions: The patient was treated with tamoxifen, an estrogen receptor modulator, as treatment for her hormone receptor positive breast cancer. One of the liver cysts was aspirated. Outcomes: In the 4.6 years after the start of tamoxifen treatment, 20 mg once daily, the volume of her liver cysts decreased remarkably. There was a reduction of combined cyst volume from 311 mL to 22 mL without percutaneous drainage. Lessons: Epidemiological as well as experimental evidence supports a pivotal role for estrogens as a driver for growth of polycystic livers. Estrogen antagonism has often been proposed as a therapeutic target, but supporting evidence is lacking in the literature. We hypothesize that the decrease in cyst size in this patient was caused by tamoxifen therapy, suggesting an in vivo antagonistic effect on cystic cholangiocytes. This is an important finding because tamoxifen could be a promising new treatment option for polycystic liver disease.